New CMS Alzheimer's drug coverage plan raises questions around worth

A Medicare plan for covering new Alzheimer's drugs treatments is reviving thorny questions about whether pricey treatments with modest success slowing the disease's progression are worth the cost and safety concerns. Driving the news: The Centers for Medicare and Medicaid Services on Thursday outlined conditions under which it would expand coverage for a specific class of Alzheimer's drugs, including Eisai and Biogen's experimental Leqembi. • The plan came a week before advisers for the Food and Drug Administration are due to weigh giving the drug full approval — which could...